# A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma

> **NCT06781112** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Weiwei Zhang** · enrollment: 35 (estimated)

## Conditions studied

- TPF
- Immunotherapy
- Nasopharyngeal Carcinoma
- Phase II Clinical Study

## Interventions

- **DRUG:** albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).

## Key facts

- **NCT ID:** NCT06781112
- **Lead sponsor:** Weiwei Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06781112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06781112, "A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06781112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*